Cart
sales@molnova.com
Kaempferol-7-O-β-D-glucopyranoside
CAS No. 16290-07-6
Kaempferol-7-O-β-D-glucopyranoside( Kaempferol-7-O-D-glucopyranoside )
Catalog No. M28330 CAS No. 16290-07-6
Kaempferol-7-O-D-glucopyranoside, a novel supercoolant could be used to sub-zero non-freezing rat heart preservation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 269 | In Stock |
|
| 5MG | 230 | In Stock |
|
| 10MG | 378 | In Stock |
|
| 25MG | 622 | In Stock |
|
| 50MG | 853 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKaempferol-7-O-β-D-glucopyranoside
-
NoteResearch use only, not for human use.
-
Brief DescriptionKaempferol-7-O-D-glucopyranoside, a novel supercoolant could be used to sub-zero non-freezing rat heart preservation.
-
DescriptionKaempferol-7-O-D-glucopyranoside, a novel supercoolant could be used to sub-zero non-freezing rat heart preservation.
-
In Vitro——
-
In Vivo——
-
SynonymsKaempferol-7-O-D-glucopyranoside
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number16290-07-6
-
Formula Weight448.38
-
Molecular FormulaC21H20O11
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC[C@H]([C@H]([C@@H]([C@H]1O)O)O)O[C@H]1Oc(cc1O)cc(OC(c(cc2)ccc2O)=C2O)c1C2=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Sellami A, Montes M, Lagarde N. Predicting Potential Endocrine Disrupting Chemicals Binding to Estrogen Receptor α (ERα) Using a Pipeline Combining Structure-Based and Ligand-Based in Silico Methods. Int J Mol Sci. 2021 Mar 11;22(6):2846.
molnova catalog
related products
-
bFGF Inhibitory Pept...
bFGF Inhibitory Peptide II
-
(Nle6)-Sarafotoxin C
(Nle6)-Sarafotoxin C
-
Ladiratuzumab
LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.
